Skip to main content
AVECHO BIOTECHNOLOGY LIMITED logo

AVECHO BIOTECHNOLOGY LIMITED — Investor Relations & Filings

Ticker · AVE ISIN · AU0000047441 LEI · 529900FA9G9T82C2LV25 ASX Manufacturing
Open in API
Filings indexed 881 across all filing types
Latest filing 2010-02-18 Regulatory Filings
Country AU Australia
Listing ASX AVE

About AVECHO BIOTECHNOLOGY LIMITED

https://avecho.com.au/

Avecho Biotechnology Limited develops and commercializes human and animal health products using its proprietary drug delivery system, Tocopheryl Phosphate Mixture (TPM®). Derived from Vitamin E, TPM® is designed to enhance the solubility and absorption of active ingredients through the skin and digestive tract. The company focuses on applying this technology to pharmaceuticals, nutraceuticals, and animal health sectors. A primary area of development includes medicinal cannabis, where Avecho has produced high-bioavailability cannabidiol (CBD) softgel capsules for therapeutic use. The company’s portfolio also includes applications in pain management and dermatology, leveraging TPM® to improve the delivery of poorly soluble molecules and enhance the efficacy of existing treatments.

Recent filings

Filing Released Lang Actions
December 2009 Appendix 4E and Statutory Financial Report 75 pages ?Kb
Regulatory Filings
2010-02-18 English
Phosphagenics Launches Australian Skincare Products 2 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is a company announcement dated 3 February 2010 about the launch of a new skincare product range by Phosphagenics. It details the exclusive sales arrangement, product features, and marketing plans. There is no financial data, regulatory filing references, or report attachments. The content is promotional and informative about a product launch rather than a financial report, management change, or regulatory filing. Therefore, it does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings. The best fitting category is a general company announcement about a product launch, which aligns with the Regulatory Filings (RNS) category as a fallback for miscellaneous announcements that do not fit other specific categories.
2010-02-02 English
Positive Results Phase 1B Study Transdermal Oxycodone Patch 3 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is a company announcement dated 1 February 2010, reporting positive results from a Phase 1B clinical study of a transdermal oxycodone patch by Phosphagenics Limited. It discusses clinical trial results, scientific details about the drug delivery system, and future development plans. There are no financial statements, regulatory filings, or management discussions of financial results. The content is focused on clinical trial outcomes and product development milestones, typical of a press release or company announcement about research progress. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is not a report publication announcement since it contains substantive information rather than just announcing a report release. The best fitting category is Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2010-01-31 English
Phosphagenics to present at ONEMEDFORUM 2010 28 pages ?Kb
Investor Presentation Classification · 95% confidence The document is a detailed investor corporate presentation by Phosphagenics Limited, including company overview, technology description, clinical trial data, market opportunities, and product pipeline updates. It is explicitly described as an "updated investor corporate presentation" used for a conference presentation. The content focuses on business strategy, technology, clinical data, and market positioning rather than financial results or regulatory filings. There is no indication that this is a formal financial report, earnings release, or regulatory filing. The document is not a brief announcement or a certification but a comprehensive presentation aimed at investors. Therefore, the most appropriate classification is Investor Presentation (IP).
2010-01-07 English
Reconciliation of Unquoted Options 2 pages ?Kb
Share Issue/Capital Change Classification · 95% confidence The document is a reconciliation of unquoted options for Phosphagenics Limited, detailing movements in option balances between 30 June 2009 and 22 December 2009. It is an announcement to the ASX (Australian Securities Exchange) regarding option movements, including lapses and balances. The document is short (2094 characters) and primarily provides a summary of option changes rather than detailed financial statements or comprehensive reports. It does not contain financial results, management discussion, or audit information. It is not a report itself but an announcement of changes in capital structure related to options. Therefore, the most appropriate classification is Share Issue/Capital Change (SHA).
2009-12-21 English
Insulin Patch On Track for Clinical Trials 2 pages ?Kb
Regulatory Filings Classification · 90% confidence The document is a company update dated 17 December 2009 from Phosphagenics Limited, announcing progress on their insulin patch clinical trials. It contains no financial statements, no regulatory form references, no voting results, no management changes, no earnings data, and no detailed financial or governance information. The text is relatively short (3940 characters) and reads like a press release or announcement about a product development milestone rather than a formal report or filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is an update on a clinical development project, which is best classified as a general regulatory announcement or company update. Given the absence of a more specific category, the best fit is Regulatory Filings (RNS), which serves as a fallback for miscellaneous announcements that do not fit other categories.
2009-12-16 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.